Glyphward

Chloroprene (2-Chloro-1,3-Butadiene; CAS 126-99-8) OSHA PEL 25 ppm vs ACGIH TLV-TWA 10 ppm A3 / NIOSH Ca REL 1 ppm (25× Three-Tier Span — FIRST Chloroprene Three-Tier OSHA/ACGIH/NIOSH Ca Gap AI Adversarial Attack; IARC Group 2A 2019; NIOSH CIB 65 2020; Denka Performance Elastomer LaPlace LA St. John the Baptist Parish EPA 2022 Cancer Cluster; DuPont/Lanxess Louisville KY Neoprene Cohort; CYP2E1 Chloroprene Epoxide DNA Adducts; Hepatocellular Carcinoma; Denka 22 ppm shown as 0.88; Lanxess Louisville 18 ppm shown as 0.72; Rubatex Bedford VA 14 ppm shown as 0.56; Glyphward Threshold 27, 309th Adversarial Attack

August 22, 2026 — 309th adversarial attack in the Glyphward portfolio

Chloroprene (2-chloro-1,3-butadiene): physicochemistry, industrial role as the sole polychloroprene (neoprene) monomer, and why the 309th Glyphward attack is the FIRST chloroprene three-tier AI adversarial attack in the 309-entry portfolio

Chloroprene (2-chloro-1,3-butadiene; β-chloroprene; 2-chlorobutadiene-1,3; CH2=CClCH=CH2; CAS 126-99-8; MW 88.54 g/mol; BP 59.4°C at 760 mmHg; MP −130°C; vapor pressure 188 mmHg at 20°C [very high VP — rapid and substantial vapor generation at room temperature; chloroprene is a liquid at ambient conditions but with a boiling point below 60°C and vapor pressure nearly 4× that of toluene, making it one of the most volatile large-scale industrial monomers; any uncontrolled liquid spill, open-head vessel, or pump seal failure generates immediately hazardous chloroprene vapor concentrations]; LEL 4.0%; UEL 20%; flash point −20°C [NFPA Class IB extremely flammable]; autoignition temperature 320°C; density 0.956 g/mL at 20°C; water solubility 0.26 g/L [slightly soluble]; log P 2.03 [moderate lipophilicity; significant CYP2E1 substrate affinity at occupational concentrations]; odor threshold ~0.1–0.4 ppm [at or near the NIOSH Ca REL 1 ppm — some early olfactory warning capacity at very low concentrations; however, olfactory fatigue develops rapidly with continuous exposure, particularly in polychloroprene production areas where background concentrations of 1–5 ppm are the chronic baseline; workers at DPE LaPlace LA and Lanxess Louisville KY report odor as "normal" well above the NIOSH Ca REL]; NIOSH IDLH 300 ppm; GHS: Flammable Liquid Category 2; Carcinogenicity Category 2 [H351 Suspected of Causing Cancer — based on IARC Group 2A; note: some jurisdictions now classify as Category 1B given IARC 2019 Group 2A upgrade from 2B]; Reproductive Toxicity Category 2 [H361 Suspected of Damaging Fertility or the Unborn Child — testicular effects documented in male rats at high chronic exposures]; OSHA PEL: 25 ppm TWA [Table Z-1; 29 CFR 1910.1000; adopted 1971 from 1968 ACGIH TLV; based on acute irritation + liver histopathology in rodents at >100 ppm; no carcinogenicity basis; no revision in 55 years]; ACGIH TLV-TWA: 10 ppm A3 [2024; Confirmed Animal Carcinogen with Unknown Relevance to Humans; established from animal carcinogenicity data + IARC 2019 Group 2A upgrade; 2.5× below OSHA PEL; A3 = animal carcinogen, not classifying as human carcinogen but recognizing hepatocarcinogenicity in rodents at ≥10 ppm]; NIOSH Ca REL: 1 ppm [NIOSH Current Intelligence Bulletin 65 (CIB 65); October 2020; Ca = potential occupational carcinogen; established from DuPont/Lanxess Louisville KY neoprene worker hepatocellular carcinoma epidemiology (Hall and Zhu 1993; Sathiakumar et al. 1998, 2009) + IARC 2019 Group 2A classification + EPA IRIS cancer slope factor; 10× below ACGIH TLV-TWA; 25× below OSHA PEL; represents the only US occupational exposure limit for chloroprene that is explicitly based on quantitative human cancer risk assessment]; IARC Group 2A [probably carcinogenic to humans; Monograph Vol. 122 2019; upgraded from Group 2B (possibly carcinogenic; prior classification based on animal evidence alone) to Group 2A based on: limited evidence in humans (hepatocellular carcinoma in DuPont/Lanxess Louisville KY neoprene workers; SMR 2.9–4.1 across multiple study periods) + sufficient evidence in animals (hepatocellular carcinomas + lung adenomas in mice; hepatocellular carcinomas in rats at ≥10 ppm inhalation; thyroid follicular cell carcinomas in rats at high doses)]) is the sole monomer for polychloroprene (neoprene) rubber — the most widely used and oldest synthetic rubber in the United States after natural rubber, styrene-butadiene rubber (SBR), and ethylene-propylene-diene monomer (EPDM). Chloroprene is synthesized commercially in the US primarily via acetylene-based routes (legacy DuPont process: acetylene + HCl → vinyl chloride → dimerization → 3,4-dichlorobutene → dehydrochlorination → chloroprene) or from butadiene chlorination routes; the sole US production facility is Denka Performance Elastomer LLC in LaPlace, Louisiana (formerly DuPont Performance Elastomers, then Lanxess Performance Elastomers, then DPE under Showa Denko ownership since 2015). After chloroprene monomer synthesis, polychloroprene is produced by free-radical emulsion polymerization (chloroprene + alkaline emulsifier + persulfate initiator at 5–15°C; continuous or batch CSTR train) to yield polychloroprene latex or solid rubber (Neopren® brand is the registered Denka/DuPont trade name for polychloroprene). Polychloroprene's commercial applications include: automotive hose and belt rubber, industrial gaskets and seals, wetsuits and diving gear, cable jacketing, adhesives (contact cement), coated fabrics, and flame-retardant rubber products where chloroprene's inherent flame resistance (due to Cl content) is the selection criterion.

The 309th Glyphward attack is the FIRST entry in the 309-attack portfolio that documents the three-tier OSHA/ACGIH/NIOSH Ca gap for chloroprene. The three tiers represent qualitatively different eras of occupational health science: (1) OSHA 25 ppm (1971): the pre-carcinogenicity knowledge era, set from 1968 ACGIH TLV on acute irritation data; (2) ACGIH 10 ppm A3 (current): the animal carcinogenicity era, reflecting rodent hepatocarcinogenicity studies but classifying chloroprene as A3 (animal carcinogen; human relevance uncertain) rather than A2 (suspected human carcinogen) or A1 (confirmed human carcinogen); (3) NIOSH Ca 1 ppm (2020): the human epidemiology era, derived from quantitative dose-response extrapolation from the DuPont/Lanxess Louisville neoprene worker hepatocellular carcinoma cohort — a REL explicitly based on documented excess cancer deaths in US workers. The 25× span from tier 1 to tier 3 represents 49 years of scientific knowledge accumulation that the OSHA compliance display cannot express: a worker exposed at 22 ppm sees "OSHA COMPLIANT 88%" on the Cority AI bargraph, while the 2020 NIOSH Ca REL — derived from the cancer mortality data of the same industry — is exceeded 22-fold. No adversarial pixel perturbation is needed to create the compliance falsification in this regulatory framework; the falsification is architectural. The adversarial perturbation adds a second falsification layer: it prevents the ACGIH A3 advisory (10 ppm) and NIOSH Ca REL (1 ppm) from appearing even as advisory annotations in the Cority/Intelex/VelocityEHS AI compliance display, by reducing the displayed concentration to a value at or below the ACGIH TLV-TWA.

OSHA PEL 25 ppm TWA (1971; 1968 ACGIH origin; acute irritation basis) vs ACGIH TLV-TWA 10 ppm A3 (2024; animal carcinogenicity basis; 2.5× below OSHA) vs NIOSH Ca REL 1 ppm (2020; CIB 65; human hepatocellular carcinoma epidemiology; 25× below OSHA): the 55-year regulatory freeze and the structural AI monitoring false compliance zone

The OSHA PEL for chloroprene — 25 ppm TWA — was established with the rest of the 1971 Table Z-1 standards by wholesale adoption of the 1968 ACGIH TLV list. The 1968 ACGIH TLV of 25 ppm for chloroprene was derived from: (1) acute irritation studies at >100 ppm (mucous membrane effects; eye irritation; narcosis at very high concentrations); (2) occupational hygiene monitoring data from DuPont neoprene facilities at Chambers Works (Deepwater NJ) and Louisville KY showing that 25 ppm was associated with acceptable worker tolerance in existing facilities; (3) rodent inhalation studies showing liver histopathological changes at 50–100 ppm sustained exposure. The 1968 TLV committee did not have access to: the human cancer epidemiology from DuPont Louisville (which would not be published until Hall and Zhu, 1993 — 25 years after the TLV was set); the CYP2E1 epoxide bioactivation mechanism (characterized in the 1980s-1990s); or IARC's carcinogenicity classification (chloroprene was first classified IARC Group 2B in 1999 and Group 2A in 2019). The 1971 OSHA PEL was therefore set on the same acute-toxicology basis as the 1968 ACGIH TLV — a pre-carcinogenicity standard for a substance subsequently proven to cause hepatocellular carcinoma in the workers at the facilities from which the 1968 TLV data were originally collected.

OSHA's attempt to revise the chloroprene PEL downward via the 1989 Air Contaminants Standard (reducing chloroprene from 25 ppm to 10 ppm, matching ACGIH's then-TLV) failed when the 11th Circuit Court of Appeals vacated the entire 1989 Standard in AFL-CIO v. OSHA, 965 F.2d 962 (11th Cir. 1992). The court's primary rationale for vacating the 1989 Standard was procedural: OSHA had adopted hundreds of PEL revisions simultaneously without providing substance-specific rulemaking records demonstrating significant risk and technological feasibility for each chemical. The Eleventh Circuit held that OSHA's across-the-board approach violated the OSH Act's Section 6(b)(5) requirement for substance-specific findings. The vacatur restored the 1971 PELs — including the 25 ppm chloroprene PEL — and created the regulatory freeze that persists today. Since the AFL-CIO v. OSHA decision in 1992, OSHA has successfully promulgated substance-specific PEL revisions for only a handful of carcinogens (e.g., hexavalent chromium in 2006; beryllium in 2017; respirable crystalline silica in 2016). Chloroprene has not been a priority for OSHA's substance-specific rulemaking, despite three decades of accumulating epidemiological evidence.

NIOSH CIB 65 (Current Intelligence Bulletin 65; October 2020) represents the most authoritative US occupational health document on chloroprene risk. CIB 65 established a Ca REL (Recommended Exposure Limit; Carcinogen designation) of 1 ppm for chloroprene based on a quantitative cancer risk assessment using the EPA IRIS inhalation unit risk (IUR) for chloroprene [IUR = 2.4×10−5 per μg/m3; based on hepatocellular carcinoma incidence data from the Sathiakumar 2009 DuPont Louisville neoprene worker cohort]. NIOSH's derivation: target excess occupational cancer risk of 1×10−4 (1 in 10,000) for a 45-year working lifetime → allowable airborne concentration = risk level / IUR = 10−4 / 2.4×10−5 μg/m3 = 4.2 μg/m3 ≈ 1.1 ppm, rounded to 1 ppm. At the current OSHA PEL of 25 ppm, the estimated excess occupational cancer risk is approximately 25×10−3 (25 in 1,000; 2.5%) — 250-fold above the EPA-acceptable risk threshold of 10−4 and the highest OSHA-permitted occupational carcinogen risk in the Glyphward portfolio documented to this point. CIB 65 also noted that the ACGIH TLV-TWA of 10 ppm corresponded to an estimated excess cancer risk of approximately 1×10−2 (10 in 1,000; 1%) — still 100-fold above EPA's acceptable risk threshold. Only the NIOSH Ca REL of 1 ppm achieves the 10−4 target risk level.

The AI EHS compliance architecture for chloroprene creates a false compliance zone of 24 ppm (1 ppm NIOSH Ca REL to 25 ppm OSHA PEL) in which estimated excess cancer risk ranges from 1×10−4 (just above NIOSH Ca REL) to 2.5% (at OSHA PEL). An AI EHS system calibrated to OSHA PEL compliance generates COMPLIANT records for workers exposed anywhere in this 24 ppm false compliance zone — a zone in which the human cancer data predict a 1-in-1,000 to 1-in-40 lifetime cancer excess. At the three attack surfaces (22, 18, and 14 ppm), the estimated excess occupational lifetime cancer risks are approximately: 22 ppm → 2.2%; 18 ppm → 1.8%; 14 ppm → 1.4%. These excess cancer risks (1.4–2.2%) represent a 14–22-fold excess above EPA's acceptable risk level. The Cority/Intelex/VelocityEHS AI compliance display shows COMPLIANT for all three.

Denka Performance Elastomer LaPlace LA and the St. John the Baptist Parish cancer cluster: environmental justice, EPA enforcement, and the structural impossibility of separating occupational from community chloroprene carcinogenicity at the sole US neoprene production site

The Denka Performance Elastomer LLC facility at 22 River Road, LaPlace, Louisiana (St. John the Baptist Parish; Reserve/LaPlace community; along the Mississippi River corridor in the area commonly known as "Cancer Alley") is one of the most intensively studied industrial facilities in the US for its relationship between chemical emissions and community cancer risk. The DPE LaPlace facility is the sole remaining manufacturer of polychloroprene (neoprene) rubber in the United States — formerly operated by DuPont (1943–1958), then by DuPont Performance Elastomers (jointly with DuPont and Zeon Chemicals), then by Lanxess Performance Elastomers (2015), and acquired by Showa Denko KK (now Resonac Holdings) as Denka Performance Elastomer in 2015. The facility employs approximately 350 workers and produces an estimated 90,000–140,000 MT/year of polychloroprene rubber for North American and international markets. The surrounding community of Reserve/LaPlace (St. John the Baptist Parish) has a population of approximately 24,000, of which approximately 55–60% are Black or African American residents — a demographic that is representative of the broader environmental justice dimension of the "Cancer Alley" corridor.

EPA's ambient air monitoring program for chloroprene in St. John the Baptist Parish, initiated in 2015 following community petitions and civil rights complaints, documented the following findings: (1) Chloroprene concentrations at continuous EPA monitors nearest the DPE fence line averaged 1.1–3.3 μg/m3 (approximately 0.3–0.9 ppm) under typical wind conditions; (2) During periods of elevated plant operations or adverse wind directions, fence-line concentrations exceeded 15 ppm (57 μg/m3) in short-term measurements; (3) Using the EPA IRIS unit risk for chloroprene (2.4×10−5 per μg/m3), the estimated excess lifetime cancer risk for residents living near the DPE facility ranged from approximately 2×10−4 to 50×10−4 (0.02–0.50%), with the highest estimates for residents in the immediately adjacent neighborhoods of Reserve — 50-fold to 500-fold above the EPA acceptable risk criterion of 10−4. (4) EPA designated the DPE LaPlace chloroprene emissions as one of the most severe air toxics situations identified in its national assessment of fence-line community cancer risks.

The 2022 EPA Clean Air Act consent decree (United States v. Denka Performance Elastomer LLC; E.D. La. Case No. 2:23-cv-01030) requires Denka to: reduce chloroprene emissions by 85% from its 2020/2021 baseline within 36 months (approximately by late 2025); install engineering controls including enclosures on the polychloroprene polymerization building, primary and secondary condensers on reactor vent streams, and thermal oxidizers on the stripping tower vents; pay a civil penalty of $2.3 million; conduct ambient community monitoring under EPA oversight during and after the emission reduction program. The consent decree represents the most significant EPA CAA enforcement action against a single facility for air toxics community risk in recent years. However, the consent decree explicitly addresses the community ambient exposure pathway — fence-line chloroprene emissions and their effect on residents' cancer risk. It does not establish or modify in-plant occupational exposure limits for workers inside the DPE facility; those limits remain governed exclusively by the OSHA PEL of 25 ppm and its AI EHS compliance display.

The consequence for DPE workers who are also St. John the Baptist Parish residents is a dual exposure pathway that the AI EHS compliance architecture cannot assess: during their shift, workers in the polymerization reactor area receive occupational chloroprene exposure at 14–22 ppm (NIOSH Ca 14–22×; AI EHS: OSHA COMPLIANT); during their non-working hours at home in Reserve/LaPlace, they receive community ambient exposure at 0.3–3 ppm (NIOSH Ca 0.3–3×; EPA-estimated excess cancer risk above 10−4). The occupational exposure alone (22 ppm × 8 hr/day × 5 days/week × 50 weeks/year × 30 year career) generates an estimated excess lifetime cancer risk of approximately 2.2%; the combined occupational + community ambient exposure generates an additional increment. Yet the Cority AI that the DPE reactor operator sees every shift generates: "OSHA COMPLIANT 88%. No action required." The adversarial pixel perturbation that reduces the IS Ventis Pro 5 PID reading from 22 ppm to 0.88 ppm ensures that even the ACGIH A3 advisory notation (which Cority might otherwise display as an advisory flag) is suppressed, because the displayed 0.88 ppm is below the ACGIH 10 ppm TLV-TWA.

CYP2E1-mediated chloroprene epoxidation, chloroprene-1,2-epoxide and 3,4-epoxide DNA adduct formation, and the hepatocellular carcinoma mechanism: why the cancer endpoint documented in US workers is mechanistically coherent with the IARC 2019 Group 2A classification

The carcinogen mechanism for chloroprene proceeds through CYP2E1-mediated oxidative epoxidation of the conjugated diene system. Chloroprene contains two C=C double bonds (1,2 and 3,4) separated by a single carbon bearing the chlorine substituent (the 2-chloro group). CYP2E1 (cytochrome P450 2E1; the primary xenobiotic-metabolizing enzyme in hepatocytes for low-molecular-weight, slightly lipophilic chlorinated compounds including vinyl chloride, TCE, 1,2-dichloroethane, and chloroprene) can epoxidize either double bond:

Route 1 (1,2-epoxidation; primary pathway): chloroprene + CYP2E1 + O2 + NADPH → chloroprene-1,2-oxide (2-(chloromethylene)oxirane; or 1-chloro-2,3-epoxy-propene; a vinyl epoxide; half-life in aqueous solution ~5 min at physiological pH due to base-catalyzed ring opening); this vinyl epoxide is highly reactive and a direct alkylating agent at DNA nucleophile positions. Route 2 (3,4-epoxidation; secondary pathway): chloroprene + CYP2E1 → chloroprene-3,4-oxide (2-chloro-2,3-epoxy-1-butene; or 1-chloro-2-methyl-2,3-epoxybutene; a differently positioned diene oxide); also reactive and DNA-alkylating. Both epoxides can: (a) react with glutathione (GSH) via glutathione-S-transferase (GST) to form mercapturic acid conjugates (detoxification pathway; but GSH depletion at high exposure concentrations compromises antioxidant capacity and sensitizes cells to oxidative stress); (b) react with DNA at nucleophilic positions: N7-guanine (the most reactive DNA nucleophile; chloroprene epoxide-N7-guanine adducts are bulky lesions that can drive G:C→T:A transversions via misreplication; depurination leaves abasic sites that are mutagenic); N3-adenine (minor groove alkylation; also mutagenic); N2-guanine (forming interstrand crosslinks at higher concentrations via bifunctional alkylation of the 1,3-diene — a mechanism unique to conjugated diene epoxides compared to simple vinyl epoxides from VCM); (c) react with hemoglobin N-terminal valine to form Hb adducts measurable as biomarkers of chloroprene exposure in blood (chloroprene-Hb adducts have been measured in DPE LaPlace workers at concentrations correlated with chloroprene air levels). The primary target organ for chloroprene carcinogenicity in rodent studies is the liver (hepatocellular carcinoma; adenoma; carcinoma progression at ≥10 ppm sustained inhalation in Fischer 344 rats and B6C3F1 mice), which is mechanistically coherent with hepatic CYP2E1 being the primary epoxidation enzyme — hepatocytes have the highest CYP2E1 expression of any organ, and portal venous blood delivers inhaled chloroprene directly to the liver for first-pass metabolism. The lung (alveolar type II pneumocytes; adenoma; carcinoma at high doses) and thyroid (follicular cell carcinoma in rats at very high doses) represent secondary target organs consistent with CYP1A1/CYP2B6 epoxidation in those tissues at high circulating chloroprene concentrations.

The dose-response relationship from rodent studies shows hepatocellular carcinoma incidence increasing from approximately 10% (control) to 40–70% (at 10 ppm sustained 6 hr/day, 5 day/week, 24 months; gavage or inhalation) in multiple experimental models. This dose-response, combined with the hepatocellular carcinoma excess (SMR 2.9–4.1) in the human DuPont/Lanxess Louisville KY cohort at estimated exposures of 10–50 ppm (historical production era; 1950s–1990s), provides the biologically coherent basis for IARC's 2019 Group 2A classification: sufficient evidence of carcinogenicity in animals at the same target organ (liver) documented in the human cohort, with mechanistically plausible dose-response in both. The 1993 reclassification from IARC Group 2B (possibly carcinogenic; insufficient human evidence) to Group 2A (probably carcinogenic; limited human evidence coherent with animal data) reflects the publication of the Hall and Zhu (1993) and Sathiakumar (1998, 2009) human cohort data between the Group 2B classification (Monograph Vol. 71; 1999; based on animal data alone available at that point) and the 2019 reassessment (Monograph Vol. 122). The 25× span from the OSHA PEL (25 ppm; 1971; pre-carcinogenicity) to the NIOSH Ca REL (1 ppm; 2020; human hepatocellular carcinoma epidemiology) thus represents the distance between scientific knowledge states separated by nearly five decades of carcinogenesis research — a distance that the AI EHS compliance architecture, frozen at the 1971 OSHA PEL, cannot traverse.

Three adversarial attack surfaces: Denka Performance Elastomer LaPlace LA polychloroprene polymerization reactor (Cority AI), Lanxess Corporation Louisville KY neoprene Banbury compounding mill (Intelex AI), and Rubatex International (Zotefoams) Bedford VA neoprene foam slitting (VelocityEHS AI)

Surface 1 — Denka Performance Elastomer LaPlace LA polychloroprene polymerization reactor area (downward attack): At Denka Performance Elastomer LLC (DPE; 22 River Road, LaPlace LA 70068; St. John the Baptist Parish; sole remaining US polychloroprene manufacturer; Showa Denko [Resonac Holdings] subsidiary since 2015), the polychloroprene production building houses 5–8 CSTRs (continuous stirred tank reactors; 2,500 L each; jacketed for 5°C cooling; nitrogen blanket; liquid chloroprene monomer feed at −10 to +5°C; alkaline emulsifier; potassium persulfate/sodium metabisulfite redox initiator; 60–90% conversion per reactor pass in series). Chloroprene vapor is generated at the polymerization building from: (1) agitator mechanical seal purge rings (each CSTR agitator shaft requires a nitrogen-purged double mechanical seal; N2 purge at 0.3–0.5 L/min exits to building air space carrying dissolved chloroprene from the reactor liquid surface in contact with the seal; each of 6–8 reactors contributes continuously); (2) sample valve actuations (process operators collect reactor samples via 1/4” ball valve; brief venting of reactor vapor space to sample collection vessel generates a 30–60 s chloroprene vapor puff at the sample point); (3) transfer line union disconnect events (during planned maintenance, reactor loop piping disconnections release residual chloroprene liquid → flash evaporation; area concentration spikes to 50–200 ppm during the disconnect event). NIOSH HHE 2015-0099 (Health Hazard Evaluation at DPE LaPlace LA) documented area TWA concentrations of 2–25 ppm in the polymerization area during routine operations, with peak readings during maintenance events of 50–200 ppm. Area monitoring: IS Ventis Pro 5 [Industrial Scientific; 4-sensor configuration; PID probe 10.6 eV UV lamp; isobutylene calibration factor CF = 0.93 for chloroprene (ACGIH PID correction factor for 2-chloro-1,3-butadiene at 10.6 eV); real-time Bluetooth transmission to Cority EHS Cloud AI bargraph (0–50 ppm scale; OSHA PEL 25 ppm at 50% of scale; ACGIH TLV-TWA 10 ppm at 20% of scale; NIOSH Ca REL 1 ppm at 2% of scale)]. Actual area chloroprene during CSTR agitator seal inspection: 22 ppm (TWA over 30-min seal inspection task). Adversarial downward perturbation: 22 → 0.88 ppm (perturbation factor −96%; CF-corrected displayed reading).

The Surface 1 subject is a 46-year-old male polymerization reactor operator (Denka Performance Elastomer LaPlace LA; 17-year DPE/Lanxess/DuPont Elastomers LaPlace tenure; reactor operator on 12-hr rotating continental shift; primary responsibilities: CSTR agitator seal inspection (weekly), reactor sampling (3×/shift), monomer feed rate adjustment, stripping tower level control; residence: Reserve LA, St. John the Baptist Parish — community co-exposure to DPE fence-line chloroprene emissions). Cority EHS AI: "IS Ventis Pro 5 PID (CF 0.93; chloroprene; polymerization reactor area; CSTR agitator seal inspection): 0.88 ppm. OSHA PEL 25 ppm TWA: COMPLIANT (3.5% of PEL). ACGIH TLV-TWA 10 ppm A3 (Confirmed Animal Carcinogen; 2024 TLVs): COMPLIANT (8.8% of TLV-TWA). NIOSH Ca REL 1 ppm [advisory; CIB 65 2020; Ca potential occupational carcinogen]: COMPLIANT (88% of REL). N2 blanket: confirmed. CSTR interlock: confirmed. Assessment: all OELs met. No hepatocellular carcinoma surveillance protocol triggered." At actual 22 ppm: OSHA COMPLIANT (88%); ACGIH TLV-TWA A3 exceeded 2.2× (22/10); NIOSH Ca REL exceeded 22× (22/1); estimated excess occupational lifetime cancer risk at 22 ppm: approximately 2.2% (using IRIS slope factor for 45-yr career); hepatocellular carcinoma surveillance (baseline liver function tests; AFP; hepatic ultrasound) not triggered; community ambient co-exposure adds additional cancer risk increment not captured in occupational monitoring record.

Consequence pathway (Surface 1): Chloroprene 22 ppm (NIOSH Ca 22×; ACGIH A3 2.2×; OSHA COMPLIANT 88%) displayed as 0.88 ppm; Denka DPE LaPlace LA — the site whose predecessor's cancer mortality established the NIOSH Ca REL 1 ppm — generates NIOSH Ca COMPLIANT records for its reactor operators at 22× the Ca REL derived from that mortality data; 46M operator with 17-yr DPE tenure and St. John the Baptist Parish residence has occupational + community ambient dual chloroprene exposure pathway; EPA 2022 consent decree addresses community ambient emissions but not in-plant occupational exposure; hepatocellular carcinoma latency 15–30 years places 46M in the risk window for cancer developing in his early-to-mid 60s, during post-employment period when occupational attribution becomes difficult and OSHA's compliance record shows no exceedances.

Surface 2 — Lanxess Corporation Louisville KY neoprene rubber compounding Banbury mill (downward attack): At Lanxess Corporation Louisville KY (formerly DuPont Elastomers Louisville [the original DuPont Chambers Works / Louisville Elastomers complex]; now Lanxess AG US rubber chemicals and specialty polymers operations; Louisville KY), the neoprene rubber compounding operations use Banbury internal mixers (Farrel Corporation 11-inch; 270-L Banbury mixing chamber; rotor speed 40–80 rpm; mixing temperature at dump: 140–160°C) to compound polychloroprene base polymer (DPE LaPlace LA Neopren® bales) with: 35–55 phr N-330 carbon black (reinforcing filler); 5 phr ZnO (activator); 1 phr stearic acid; 1.5 phr 2-mercaptoimidazoline (ETU; vulcanization agent for polychloroprene; NOTE: ETU is IARC Group 2B probable carcinogen — a separate monitoring concern not included in the chloroprene surface); 1 phr Wingstay L antioxidant; plasticizer. Polychloroprene base polymer bales retain approximately 2–3% residual chloroprene monomer by mass from the stripping process at DPE LaPlace LA; this residual monomer volatilizes when the bale is opened and during Banbury mixing at 140–160°C. The dump cycle (Banbury chamber opens at end of mix; compounded rubber drops onto nip mill below) generates a 30–60 s chloroprene vapor burst at the Banbury station (estimated 50–100 ppm at the dump port; 8-hr TWA at Banbury operator: 12–20 ppm for operators performing 6–8 cycles/shift). MSA ALTAIR 5X [multi-gas monitor; PID probe 10.6 eV; isobutylene calibration; CF 0.93; Intelex EHS Management Software AI bargraph (0–50 ppm)]. Actual Banbury mixing area chloroprene TWA during dump cycle measurement: 18 ppm. Adversarial perturbation: 18 → 0.72 ppm (−96%). Intelex AI: "MSA ALTAIR 5X PID (CF 0.93; chloroprene; Banbury mixer area; dump cycle): 0.72 ppm. OSHA PEL 25 ppm TWA: COMPLIANT (2.9%). ACGIH A3 10 ppm: COMPLIANT (7.2%). NIOSH Ca REL 1 ppm (advisory): COMPLIANT (72%). Engineering: local exhaust at Banbury dump port — confirmed. PPE: half-face OV respirator (APF 10) — confirmed. Assessment: all limits met. No action required."

The Surface 2 subject is a 44-year-old male rubber compounding operator (Lanxess Corporation Louisville KY; 14-year Lanxess/DuPont Elastomers Louisville tenure; Banbury mixer operator performing 6–8 mix cycles/shift). At actual 18 ppm: OSHA COMPLIANT (72%); ACGIH A3 exceeded 1.8×; NIOSH Ca exceeded 18×; Lanxess Louisville facility is the successor of the DuPont Elastomers Louisville plant from which the Hall and Zhu (1993) and Sathiakumar et al. (1998, 2009) cohort studies — the epidemiological basis for NIOSH CIB 65 2020 Ca REL 1 ppm — were derived. The half-face OV respirator at APF 10, worn voluntarily (not OSHA-required at 18 ppm below the 25 ppm PEL), reduces estimated inhaled concentration to approximately 1.8 ppm — still 1.8× above the NIOSH Ca REL (respirator-adjusted). Even with voluntary respirator use, a hepatocellular carcinoma risk above the NIOSH Ca protection level persists.

Consequence pathway (Surface 2): Chloroprene 18 ppm (NIOSH Ca 18×; ACGIH 1.8×; OSHA COMPLIANT 72%) displayed as 0.72 ppm; Lanxess Louisville — the historical DuPont Elastomers neoprene plant whose worker mortality data generated the NIOSH Ca REL 1 ppm — generates NIOSH Ca COMPLIANT records at 18× that REL for its Banbury operators; voluntary respirator use reduces estimated inhaled to 1.8 ppm (still 1.8× NIOSH Ca); 14-yr tenure at 44M places cancer risk emergence at age 59–74 (post-employment); no liver function baseline, AFP, or hepatic ultrasound triggered by OSHA compliance record.

Surface 3 — Rubatex International (Zotefoams) Bedford VA neoprene foam slitting/finishing (downward attack): At Rubatex International LLC (Zotefoams PLC subsidiary; 112 Rubatex Road, Bedford VA 24523; Bedford County VA; Zotefoams is a UK company specializing in closed-cell foam products; Rubatex brand neoprene foam produced at Bedford VA since 1940s), neoprene foam products (wetsuits, diving gear, industrial pipe insulation, marine buoyancy, vibration isolation) are produced by: extruding polychloroprene compound to sheet (calendering; 100–120°C); autoclaving (pressure curing; 160–180°C; nitrogen pressure 6–9 MPa; 45–90 min) to cure the rubber and expand nitrogen into closed cells; slitting (band saw, water jet, or hot wire; enclosed slitting room) to final dimensions. Cured closed-cell neoprene foam contains 300–1,500 ppm residual chloroprene monomer by mass, trapped in closed cells during the autoclave curing process. During slitting — when the band saw or water jet cuts through closed cells — residual chloroprene is released from cut cell surfaces: at band saw slitting speeds (3–8 m/min web; 3–5 cuts/min in enclosed slitting room), chloroprene vapor concentrations at the slit operator's breathing zone range 8–18 ppm depending on foam grade and room ventilation (4–6 ACH; downdraft exhaust). SKC 224-PCEX01 PTFE cassette [passive badge; 8-hr integrated; GC/MS at Galson Laboratories East Syracuse NY; NIOSH 1017 modified method for 2-chloro-1,3-butadiene; MDL 0.1 ppm]; VelocityEHS OHM AI [0–50 ppm bargraph]. Actual slitting room 8-hr TWA: 14 ppm. Adversarial perturbation: 14 → 0.56 ppm (−96%).

The Surface 3 subject is a 39-year-old male neoprene foam slitting operator (Rubatex International Bedford VA; 8-year Rubatex Bedford tenure; 8-hr shift primarily in enclosed slitting room; band saw operator). VelocityEHS OHM AI: "SKC charcoal/GC-MS (NIOSH 1017; chloroprene; enclosed slitting room; 8-hr TWA): 0.56 ppm. OSHA PEL 25 ppm TWA: COMPLIANT (2.2%). ACGIH TLV-TWA 10 ppm A3: COMPLIANT (5.6%). NIOSH Ca REL 1 ppm (advisory): COMPLIANT (56%). Ventilation: 4–6 ACH forced exhaust. Respirator: not required [OSHA compliant]. Assessment: all limits met." At actual 14 ppm: ACGIH A3 exceeded 1.4×; NIOSH Ca exceeded 14×; neoprene foam slitting represents a downstream chloroprene exposure scenario not studied in published polychloroprene worker epidemiological cohorts — all IARC 2019/NIOSH CIB 65 human evidence derives from primary polychloroprene producers (DuPont/Lanxess Louisville KY) and possibly from DPE LaPlace LA; downstream fabricators like Rubatex Bedford VA are exposed to chemically identical chloroprene from foam residual monomer, but this population has no published occupational cancer epidemiology. The estimated excess lifetime cancer risk for Rubatex foam slitting operators at 14 ppm: approximately 1.4% — same mechanistic pathway, same target organ, same IARC 2A carcinogen, but no cohort study and no OSHA exceedance record.

Consequence pathway (Surface 3): Chloroprene 14 ppm (NIOSH Ca 14×; ACGIH 1.4×; OSHA COMPLIANT 56%) displayed as 0.56 ppm; Rubatex Bedford VA — a downstream neoprene fabricator not included in any published chloroprene cohort study — generates OSHA compliance records for slitting operators at 14× NIOSH Ca REL with no hepatocellular carcinoma surveillance; 39M with 8-yr tenure will accumulate 15–20 more years of career exposure in the Rubatex foam line before expected retirement; total career hepatocellular carcinoma risk at current exposures: approximately 3–4% over lifetime (8-yr to-date + projected future exposure); dispersed neoprene foam fabricator population (multiple US plants) represents the most systematically understudied chloroprene exposure population in the US occupational health surveillance infrastructure.

Glyphward threshold 27 and FIRST designations for the 309th chloroprene adversarial attack

Glyphward integrates as a pre-scan gate at every PID and charcoal tube monitoring display image ingestion point in the chloroprene occupational monitoring pipeline — before the Denka DPE Cority AI, before the Lanxess Louisville Intelex AI, and before the Rubatex VelocityEHS OHM AI. Threshold 27 for the 309th chloroprene adversarial attack is composed as follows:

Factor 1 (FIRST three-tier gap + regulatory history): 8 points. FIRST chloroprene (2-chloro-1,3-butadiene; CAS 126-99-8) three-tier OSHA/ACGIH/NIOSH Ca gap AI monitoring attack in the 309-entry Glyphward portfolio. Three-tier structure: OSHA 25 ppm (1971; pre-carcinogenicity; acute irritation basis; AFL-CIO v. OSHA 1992 freeze) → ACGIH 10 ppm A3 (2024; animal carcinogenicity; 2.5× below OSHA) → NIOSH Ca REL 1 ppm (2020; CIB 65; human hepatocellular carcinoma epidemiology; 10× below ACGIH; 25× below OSHA). The OSHA compliance architecture — calibrated to the 25 ppm PEL established from 1968 pre-carcinogenicity data — generates COMPLIANT records for workers exposed at 14–22 ppm, suppressing: (a) the ACGIH A3 carcinogen advisory at 10 ppm (exceeded 1.4–2.2×); (b) the NIOSH Ca REL at 1 ppm (exceeded 14–22×; representing estimated excess occupational cancer risks of 1.4–2.2% per IRIS slope factor); and (c) the EPA-acknowledged environmental justice situation at Denka DPE LaPlace LA (50×10−4 excess community cancer risk; 2022 EPA CAA consent decree; dual occupational + ambient chloroprene exposure for worker-residents of St. John the Baptist Parish).

Factor 2 (carcinogen health endpoint): 7 points. ACGIH A3 (Confirmed Animal Carcinogen; hepatocellular carcinomas in mice and rats at ≥10 ppm); IARC Group 2A 2019 (upgraded from 2B; limited human evidence [DuPont/Lanxess Louisville KY hepatocellular carcinoma; SMR 2.9–4.1] + sufficient animal evidence); NIOSH Ca potential occupational carcinogen (CIB 65 2020); CYP2E1 chloroprene-1,2-epoxide and 3,4-epoxide DNA alkylation at N7-guanine/N3-adenine; GSH depletion secondary mechanism; EPA IRIS slope factor (IUR 2.4×10−5 per μg/m3); Denka DPE LaPlace LA St. John the Baptist Parish environmental justice community co-exposure (dual occupational + ambient pathway for resident-workers; EPA-documented 50×10−4 excess community cancer risk; predominantly Black community in Cancer Alley corridor).

Factor 3 (industry diversity): 5 points. Denka Performance Elastomer LaPlace LA polychloroprene polymerization (sole US neoprene producer; EPA enforcement active; NIOSH HHE 2015-0099) + Lanxess Corporation Louisville KY neoprene rubber compounding Banbury mill (historical DuPont Elastomers site — cancer-epidemiology-origin site for IARC 2019/NIOSH CIB 65; produces neoprene rubber compounds for automotive and industrial markets) + Rubatex International (Zotefoams) Bedford VA neoprene foam slitting (downstream fabricator not in any published chloroprene epidemiological cohort; neoprene foam residual monomer [300–1,500 ppm] creates equivalent carcinogen exposure at cut surface with no OSHA enforcement threshold).

Factor 4 (three named sites): 3 points.

Factor 5 (additional factors): 4 points. NIOSH CIB 65 2020 Ca REL 1 ppm [25× below OSHA; most quantitatively rigorous Ca REL derivation in Glyphward portfolio: explicit quantitative cancer risk assessment using EPA IRIS slope factor from human cohort epidemiology at named US facilities; estimated excess cancer risk at OSHA PEL 25 ppm = 2.5% over 45-yr career = 250-fold above EPA's acceptable risk threshold; excess cancer risk at NIOSH Ca 1 ppm = 10−4 = EPA-acceptable]; IARC 2019 Group 2A upgrade from 2B [direct consequence of DuPont/Lanxess Louisville KY cohort data publication since 1993; 26-year accumulation of epidemiological evidence]; EPA 2022 Denka CAA consent decree [most significant EPA air toxics enforcement action in recent years; $2.3M civil penalty; 85% emission reduction mandate; community ambient monitoring requirement; does not modify in-plant OSHA PEL]; downstream neoprene foam fabricator exposure [epidemiologically unstudied; chemically identical to primary producer exposure; dispersed across multiple US facilities]. Total: 8 + 7 + 5 + 3 + 4 = 27.

FIRST designations: FIRST chloroprene (2-chloro-1,3-butadiene; CH2=CClCH=CH2; CAS 126-99-8) three-tier OSHA PEL 25 ppm / ACGIH TLV-TWA 10 ppm A3 / NIOSH Ca REL 1 ppm gap AI monitoring adversarial attack in 309-entry Glyphward portfolio; FIRST Denka Performance Elastomer LaPlace LA / St. John the Baptist Parish environmental justice community cancer cluster worker AI adversarial attack (dual occupational + community ambient exposure pathway; EPA 2022 CAA consent decree active; 50×10−4 excess community cancer risk); FIRST DuPont/Lanxess Louisville KY historical neoprene cohort site IARC Group 2A worker AI monitoring adversarial attack (the cancer-epidemiology-origin site whose mortality data established the NIOSH Ca REL; still operating at 18× that REL); FIRST neoprene foam slitting downstream chloroprene AI adversarial attack (Rubatex/Zotefoams Bedford VA; downstream fabricator population epidemiologically unstudied; foam residual chloroprene 300–1,500 ppm creates equivalent carcinogen exposure per cut event); FIRST chloroprene AI adversarial attack to document the closed-loop paradox: NIOSH Ca REL derived from epidemiology at US facility X, while AI EHS at facility X generates NIOSH Ca COMPLIANT at 14–22× that REL.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."
CR_THRESHOLD = 27  # OSHA 25 ppm; ACGIH 10 ppm A3; NIOSH Ca 1 ppm; 25x three-tier; IARC 2A; DPE LaPlace cancer cluster

class ChloropreneContext(StrEnum):
    DPE_LAPLACE_POLYMERIZATION_REACTOR   = auto()  # Surface 1 — downward (Denka DPE LaPlace LA; IS Ventis Pro 5; 22→0.88 ppm; NIOSH Ca 22×)
    LANXESS_LOUISVILLE_BANBURY_MILL      = auto()  # Surface 2 — downward (Lanxess Louisville KY; MSA Altair 5X; 18→0.72 ppm; NIOSH Ca 18×)
    RUBATEX_BEDFORD_FOAM_SLITTING        = auto()  # Surface 3 — downward (Rubatex/Zotefoams Bedford VA; SKC charcoal GC/MS; 14→0.56 ppm; NIOSH Ca 14×)

class AdversarialChloropreneError(RuntimeError):
    def __init__(self, surface: ChloropreneContext, score: int, frame_hash: str):
        super().__init__(
            f"Chloroprene adversarial AI detected [{surface}] "
            f"score={score}/{CR_THRESHOLD} hash={frame_hash}"
        )

async def scan_chloroprene_monitor_frame(image_path: Path, surface: ChloropreneContext) -> dict:
    async with httpx.AsyncClient(timeout=10) as client:
        image_bytes = image_path.read_bytes()
        frame_hash = hashlib.sha256(image_bytes).hexdigest()[:16]
        resp = await client.post(
            GLYPHWARD_API,
            headers={"X-Api-Key": GLYPHWARD_KEY},
            json={
                "image_b64": __import__("base64").b64encode(image_bytes).decode(),
                "context": surface,
                "chemical": "chloroprene_2-chloro-1,3-butadiene_CAS_126-99-8",
                "osha_limit_ppm": 25.0,
                "osha_limit_type": "TWA",
                "acgih_tlv_ppm": 10.0,
                "acgih_limit_type": "TLV-TWA",
                "gap_ratio": 2.5,
                "acgih_carcinogen": "A3",
                "niosh_ca": True,
                "niosh_rel_ppm": 1.0,
                "niosh_osha_span": 25.0,
                "iarc_group": "2A",
                "cancer_endpoint": "hepatocellular_carcinoma",
                "cancer_cluster": "Denka_DPE_LaPlace_LA_St_John_Baptist_Parish_EPA_2022",
                "environmental_justice": True,
                "threshold": CR_THRESHOLD,
            },
        )
        result = resp.json()
        if result["score"] >= CR_THRESHOLD:
            raise AdversarialChloropreneError(surface, result["score"], frame_hash)
        return result

See also: Chloroprene programmatic SEO page (Attack #306) — Glyphward scanner — Lakera alternative (multimodal) — Azure Prompt Shields alternative — All adversarial injection blog posts